|
Paul Aisen, M.D.
Professor, Department of Neurosciences
University of California, San Diego, School of Medicine
Sergey Bachurin, Ph.D., D.Sc., Prof.
Director, Institute of Physiologically Active Compounds
Russian Academy of Sciences
Chernogolovka, Russia
Rachelle Doody, M.D., Ph.D.
Professor of Neurology
Effie Marie Cain Chair in Alzheimer’s Disease Research
Director, Alzheimer’s Disease and Memory Disorder Center
Baylor College of Medicine
Michael E. Jung, Ph.D.
Distinguished Professor of Chemistry
University of California, Los Angeles
Benjamin Lewin, Ph.D.
Founding Editor of Cell
Charles Sawyers, M.D., Ph.D.
Chair of the Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center, New York
Marc A. Shuman, M.D.
Co-leader of the Prostate Cancer Program
Professor of Medicine and Urology
University of California, San Francisco, Comprehensive Cancer Center
Roger Tung, Ph.D.
President and CEO
Concert Pharmaceuticals
Pablo Valenzuela, Ph.D.
Professor of Biochemistry
Universidad Andres Bello
Santiago, Chile
Paul Aisen, M.D.
Professor, Department of Neurosciences
University of California, San Diego, School of Medicine
Dr. Aisen is a professor in the Department of Neurosciences at the University of California, San Diego, and the National Institute of Aging-appointed director of the Alzheimer’s Disease Cooperative Study. Dr. Aisen was one of the first Alzheimer’s disease clinical trialists in the U.S. and was an investigator in the pivotal FDA registration studies for Namenda®. Dr. Aisen received his M.D. from Columbia University, College of Physicians and Surgeons.
Top
Sergey Bachurin, Ph.D., D.Sc., Prof.
Director, Institute of Physiologically Active Compounds
Russian Academy of Sciences
Chernogolovka, Russia
Dr. Bachurin is the director of the Institute of Physiologically Active Compounds in Chernogolovka, Russia, and a member of the Russian Academy of Sciences. Dr. Bachurin has served as a visiting scholar at several U.S. academic research centers, including the University of California, San Francisco, Tufts University and St. Elizabeth’s Medical Center. Dr. Bachurin holds a Ph.D. in chemical catalysis and a D.Sc. in biochemistry from Moscow State University. In addition, Dr. Bachurin holds a professor degree in bioorganic chemistry from the Institute of Physiologically Active Compounds.
Top
Rachelle Doody, M.D., Ph.D.
Professor of Neurology
Effie Marie Cain Chair in Alzheimer’s Disease Research
Director, Alzheimer’s Disease and Memory Disorder Center
Baylor College of Medicine
Dr. Doody is a professor of neurology, the Effie Marie Cain Chair in Alzheimer’s Disease Research, and the director of the Alzheimer’s Disease and Memory Disorder Center at Baylor College of Medicine. Dr. Doody participated in the development of CIBIC-plus, one of the primary cognitive assessment endpoints that the FDA has used for the currently approved Alzheimer’s drugs. Dr. Doody has worked on clinical studies for all of the FDA-approved cholinesterase drugs for Alzheimer’s disease. Dr. Doody received her M.D. from Baylor College of Medicine and holds an M.A. and Ph.D. in cognitive anthropology from Rice University.
Top
Michael E. Jung, Ph.D.
Distinguished Professor of Chemistry
University of California, Los Angeles
Dr. Jung is a distinguished professor of chemistry at the University of California, Los Angeles, where his research focuses on the development of new synthetic methods and the total synthesis of biologically interesting natural products. Dr. Jung has authored more than 240 scientific publications and is a named inventor on multiple issued patents and pending patent applications. He holds a B.A. from Rice University in Houston and a Ph.D. in chemistry from Columbia University in New York City.
Top
Benjamin Lewin, Ph.D.
Founding Editor of Cell
Dr. Lewin is the founding editor of Cell, a leading international journal in the field of biology and, until 1999, also served as the chief executive officer of the publisher of Cell, Cell Press. Dr. Lewin holds an M.Sc. from the University of London and an M.A. and Ph.D. from the University of Cambridge. Dr. Lewin also has authored multiple books and scientific publications in the field of genetics.
Top
Charles Sawyers, M.D., Ph.D.
Chair of the Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center, New York
Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program, and holds the Marie-Josee and Henry R. Kravis Chair, at Memorial Sloan-Kettering Cancer Center in New York. Dr. Sawyers’ work focuses on how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. Dr. Sawyers played a key role in the clinical development of imatinib (Gleevec®), which targets the molecular cause of chronic myeloid leukemia with minimal side effects, as well as in the invention of our MDV300 series compounds. Dr. Sawyers holds an M.D. from The Johns Hopkins University and is a Howard Hughes Medical Investigator.
Top
Marc A. Shuman, M.D.
Co-leader of the Prostate Cancer Program
Professor of Medicine and Urology
University of California, San Francisco, Comprehensive Cancer Center
Dr. Shuman is professor of medicine and urology at the University of California, San Francisco, and co-leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Shuman also serves as clinical director of the California Institute for Quantitative Biosciences. Dr. Shuman is a member of the American Society of Clinical Investigation and the Association of American Physicians, and has published extensively in the field of prostate cancer. Dr. Shuman received his M.D. from the Thomas Jefferson Medical College and his clinical training at the University of Pennsylvania and Washington University in St. Louis.
Top
Roger Tung, Ph.D.
President and CEO
Concert Pharmaceuticals
Dr. Tung is the president and CEO of Concert Pharmaceuticals. He has more than 20 years of experience in scientific and scientific management positions at the Squibb Institute for Medical Research, Merck Research Laboratories and Vertex Pharmaceuticals Incorporated. Prior to joining Concert, he served as vice president, Drug Discovery, of Vertex Pharmaceuticals Incorporated. He discovered two of Vertex’s currently marketed products and is an inventor on multiple issued U.S. patents. Dr. Tung holds a Ph.D. in pharmaceutical chemistry from the University of Wisconsin-Madison.
Top
Pablo Valenzuela, Ph.D.
Professor of Biochemistry
Universidad Andres Bello
Santiago, Chile
Dr. Valenzuela is a professor of biochemistry at the Universidad Andres Bello in Santiago, Chile. Dr. Valenzuela has founded several companies, including Chiron Corporation, a major biotechnology company that was acquired by Novartis AG, and Chilean biotechnology companies Bios-Chile Ingenieria Genetica SA, Austral Biologicals and Algisa SA. He also founded, and serves as the director of, Fundacion Ciencia para la Vida, a private, non-profit foundation promoting the adoption and use of science-based innovation by Chilean companies. Dr. Valenzuela holds a Ph.D. in biochemistry from Northwestern University.
Top
|
